



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffery T. Helvey
Heidi L. Kraus
Crystal D. Sayles
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II
Eldora Ellison Floyd
W. Russell Swindell

Thomas J. Pala
Brian J. Del Buono
Virgil Lee Beaston
Reginald D. Lucas
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III

Registered Patent Agents
Karen R. Markovitz
Andrea J. Kama
Nancy J. Leith
Joseph M. Conrad
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longswort
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in New York

MAR 14 2002

RECEIVED
FEBRUARY 16 2002

March 12, 2002

INTERNET ADDRESS:

JGOLD@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Art Unit 1633

Re: U.S. Utility Patent Application
Appl. No. 09/964,412; Filed: September 28, 2001
For: **Transgenic Animals and Cell Lines for Screening Drugs
Effective for the Treatment or Prevention of Alzheimer's
Disease**
Inventors: de la Monte *et al.*
Our Ref: 0609.4370004/RWE/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Listing of the cited documents on Form PTO-1449 (9 sheets);
3. A copy of each of the forty (40) cited documents on Form PTO-1449; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 12, 2002
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

RWE:FRC:dcw
Enclosures

P:\USERS\DWRIGHT\General\ROB ESMOND\IDS-SKGF-CV-LTR-0609.4370004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAR 14 2002
TECH CENTER 1600/2900

In re application of:

de la Monte *et al.*

Appl. No. 09/964,412

Filed: September 28, 2001

For: **Transgenic Animals and Cell
Lines for Screening Drugs
Effective for the Treatment or
Prevention of Alzheimer's Disease**

Confirmation No. 2051

Art Unit: 1633

Examiner: *To be assigned*

Atty. Docket: 0609.4370004/RWE/FRC

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regards to non-English language document AL1 cited on Form PTO 1449:

Document AL1, European Patent No. EP 0 263 740, is in the French language. An English language abstract of document AL1 is attached as document AT7.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications which are directed to related technical subject matter: U.S. Patent Application No. 09/380,203, filed April 25, 2000; U.S. Patent Application No. 09/964,678, filed September 28, 2001; U.S. Patent Application No. 09/964,666, filed September 28, 2001;

and U.S. Patent Application No. 09/964,667, filed September 28, 2001. The specifications of these applications are identical to one another, and are therefore "substantially cumulative." Accordingly, pursuant to 37 CFR § 1.98(c), a single copy of this specification is submitted herewith as document AS8. The claims currently pending from US patent application Nos. 09/380,203, 09/964,678, 09/964,666, and 09/964,667 are additionally submitted herewith as documents AT8, AR9, AS9 and AT9, respectively.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: March 12, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600



TECH CENTER 1600/2800
MAR 14 2002
Page 1 of 9

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRC

APPLICATION NO.
09/964,412

APPLICANT
de la Monte *et al.*

FILING DATE
September 28, 2001

GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,873,191	10/10/1989	Wagner <i>et al.</i>	435	172.3	08/18/1986
	AB1	5,168,053	12/01/1992	Altman <i>et al.</i>	435	91	08/17/1990
	AC1	5,830,670	11/03/1998	de la Monte <i>et al.</i>	435	7.2	05/30/1995
	AD1	5,948,634	09/07/1999	de la Monte <i>et al.</i>	435	69.1	11/14/1994
	AE1	5,948,888	09/07/1999	de la Monte <i>et al.</i>	530	350	05/30/1995
	AF1	6,071,705	06/06/2000	Wands <i>et al.</i>	435	7.1	06/06/1995
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	EP 0 263 740	04/13/1988	Europe			X Yes No
	AM1	WO 89/03849	05/05/1989	WIPO			Yes No
	AN1	WO 90/06993	06/28/1990	WIPO			Yes No
	AO1	WO 92/07065	04/30/1992	WIPO			Yes No
	AP1	WO 94/23756	10/27/1994	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Anderson, W.F., "Human gene therapy," <i>Nature</i> 392:25-30, Macmillan Journals Ltd. (April 1998).
	AS	1	Bloch, D.B., <i>et al.</i> , "Identification and Characterization of a Leukocyte-specific Component of the Nuclear Body," <i>J. Biol. Chem.</i> 271:29198-29204, The American Society for Biochemistry and Molecular Biology, Inc. (November 1996).
	AT	1	Brinster, R.L., <i>et al.</i> , "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs," <i>Proc. Natl. Acad. Sci. USA</i> 82:4438-4442, National Academy of Sciences (1985).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

MAR 14 2002
Page 2 of 9

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRC

APPLICATION NO.
09/964,412

APPLICANT
de la Monte *et al.*

FILING DATE
September 28, 2001

GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 96/15272	05/23/1996	WIPO			Yes No
	AM2	WO 96/40895	12/19/1996	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Chiu, T.-L. and Goldstein, R.A., "Optimizing energy potentials for success in protein tertiary structure prediction," <i>Folding and Design</i> 3:223-228, Current Biology Ltd. (May 1998).
	AS	2	de la Monte, S.M., <i>et al.</i> , "Enhanced Expression of an Exocrine Pancreatic Protein in Alzheimer's Disease and the Developing Human Brain," <i>J. Clin. Invest.</i> 86:1004-1013, The American Society for Clinical Investigation, Inc. (1990).
	AT	2	de la Monte, S.M., <i>et al.</i> , "Regional and Maturation-associated Expression of Endothelin 2 in Rat Gastrointestinal Tract," <i>J. Histochem. Cytochem.</i> 43:203-209, The Histochemical Society, Inc. (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRCAPPLICATION NO.
09/964,412APPLICANT
de la Monte *et al.*FILING DATE
September 28, 2001GROUP
1633Page 3 of 3
MAR 14 2002
TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	de la Monte, S.M., <i>et al.</i> , "Aberrant GAP-43 Gene Expression in Alzheimer's Disease," <i>Am. J. Pathol.</i> 147:934-946, American Society for Investigative Pathology (1995).
	AS	<u>3</u>	de la Monte, S.M., and Bloch, K.D., "Aberrant Expression of the Constitutive Endothelial Nitric Oxide Synthase Gene in Alzheimer Disease," <i>Mol. Chem. Neuropathol.</i> 30:139-159, Humana Press, Inc. (January/February 1997).
	AT	<u>3</u>	Games, D., <i>et al.</i> , "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> 373:523-527, Macmillan Journals Ltd. (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

Page 1 of 9
MAR 14 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRCAPPLICATION NO.
09/964,412APPLICANT
de la Monte *et al.*FILING DATE
September 28, 2001GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Gossler, A., <i>et al.</i> , "Transgenesis by means of blastocyst-derived embryonic stem cell lines," <i>Proc. Natl. Acad. Sci. USA</i> 83:9065-9069, National Academy of Science (1986).
	AS	<u>4</u>	Gross, J., <i>et al.</i> , "Isolation, Characterization, and Distribution of an Unusual Pancreatic Human Secretory Protein," <i>J. Clin. Invest.</i> 76:2115-2126, The American Society for Clinical Investigation, Inc. (1985).
	AT	<u>4</u>	The Huntington's Disease Collaborative Research Group, "A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes," <i>Cell</i> 72:971-983, Cell Press (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

Page 1 of 1
MAR 14 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRCAPPLICATION NO.
09/964,412APPLICANT
de la Monte *et al.*FILING DATE
September 28, 2001GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Kosaka, K., "Dementia and Neuropathology in Lewy Body Disease," <i>Adv. Neurol.</i> 60:456-463, Raven Press, Ltd. (1993).
	AS	<u>5</u>	Lannfelt, L., <i>et al.</i> , "Alzheimer's disease: molecular genetics and transgenic animal models," <i>Behav. Brain Res.</i> 57:207-213, Elsevier Science B.V. (1993).
	AT	<u>5</u>	Marx, J., "Major Setback for Alzheimer's Models," <i>Science</i> 255:1200-1202, American Association for the Advancement of Science (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED
MAR 14 2002
Page 9 of 9
TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4370004/RWE/FRC	APPLICATION NO. 09/964,412
	APPLICANT de la Monte <i>et al.</i>	
	FILING DATE September 28, 2001	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>6</u>	Ozturk, M., <i>et al.</i> , "Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain," <i>Proc. Natl. Acad. Sci. USA</i> 86:419-423, National Academy of Sciences (1989).	
AS	<u>6</u>	Pursel, V.G., <i>et al.</i> , "Genetic Engineering of Livestock," <i>Science</i> 244:1281-1288, American Association for the Advancement of Science (1989).	
AT	<u>6</u>	Quon, D., <i>et al.</i> , "Formation of β -amyloid protein deposits in brains of transgenic mice," <i>Nature</i> 352:239-241, Macmillan Journals Ltd. (1991).	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRCAPPLICATION NO.
09/964,412APPLICANT
de la Monte *et al.*FILING DATE
September 28, 2001GROUP
1633RECEIVED
MAR 14 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Salter, D.W., <i>et al.</i> , "Transgenic Chickens: Insertion of Retroviral Genes into the Chicken Germ Line," <i>Virology</i> 157:236-240, Academic Press, Inc. (1987).
	AS	Z	Verma, I.M. and Somia, N., "Gene Therapy- promises, problems and prospects," <i>Nature</i> 389:239-242, Macmillan Journals Ltd. (September 1997).
	AT	Z	Dialog File 351, Accession No. 88-100135/198815, Derwent WPI English language abstract for EP 0 263 740 (Document AL1).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

Page 8
MAR 14 2002
RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRC

APPLICATION NO.
09/964,412

APPLICANT
de la Monte *et al.*

FILING DATE
September 28, 2001

GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	International Search Report for International Application No. PCT/US98/03685, mailed July 9, 1998.
	AS	<u>8</u>	Pending Non-Provisional U.S. Patent Application No. 09/380,203, de la Monte <i>et al.</i> , filed April 25, 2000 and U.S. Patent Application Nos. 09/964,678, 09/964,666 and 09/964,667, de la Monte <i>et al.</i> , filed September 28, 2001.
	AT	<u>8</u>	Claims Currently Pending from U.S. Appl. No. 09/380,203, de la Monte <i>et al.</i> , filed April 25, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 9 of 9
MAR 14 2002
TECH CENTER 1600/2900

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4370004/RWE/FRC

APPLICATION NO.
09/964,412

APPLICANT
de la Monte *et al.*

FILING DATE
September 28, 2001

GROUP
1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Claims Currently Pending from U.S. Appl. No. 09/964,678, de la Monte <i>et al.</i> , filed September 28, 2001.
	AS	2	Claims Currently Pending from U.S. Appl. No. 09/964,666, de la Monte <i>et al.</i> , filed September 28, 2001.
	AT	2	Claims Currently Pending from U.S. Appl. No. 09/964,667, de la Monte <i>et al.</i> , filed September 28, 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.